Brainchild Bio is Growing!! We are making strategic investments in Talent to grow our team and serve our mission. If you are motivated to develop safe and effective therapies so children with cancer can grow and thrive, Brainchild Bio is for you! If you want to work alongside passionate, driven and collaborative teammates, Brainchild Bio is for you! Check out our Careers Page to see all of our open roles.
BrainChild Bio
Biotechnology Research
BrainChild Bio is harnessing the power of CAR-T cell technology for tumors in the central nervous system.
About us
We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.
- Website
-
www.brainchildbio.com
External link for BrainChild Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at BrainChild Bio
-
Katy Crowley
Cell & Gene Therapy | Lab startup | CMC | Process Characterization | Project Management | Change Control | Tech Transfer | Continuous Improvement |…
-
Steven Brugger
Biotechnology and Pharmaceuticals
-
michael jensen, md
Founder, BrainChild Bio
-
Jonathan Collins, MBA
Global HR Strategist | Husband & Dad | Aspirational Golfer | Dog Lover
Updates
-
This GeekWire article digs into our story, our collaboration with Seattle Children's and what sets BrainChild Bio apart. #DIPG #CNStumors #CARTcells #BrainChildTargetsCNSCancer
-
We are building an expansive platform that prioritizes children first and then expands our technology to additional pediatric and adult indications. #DIPG #CNStumors #brainmets #CARTcells #BrainChildTargetsCNSCancer
BrainChild Bio, Inc.
brainchildbio.com
-
We’re excited to unveil BrainChild Bio to the DIPG and cancer drug discovery communities. Fierce Biotech explores our approach to targeting #CNStumors, clinical trial in #DIPG and broader application in adult brain tumors and metastases.
‘Kid-first’ startup BrainChild wants to shift the paradigm on pediatric cancer drugs
fiercebiotech.com
-
BrainChild Bio is on a mission to harness the power of CAR-T technology in brain tumors, prioritizing children first, so they can grow up and thrive. #DIPG #CNStumors #CARTcells #BrainChildTargetsCNSCancer https://lnkd.in/ee4Seuwf
-
-
Today BrainChild Bio, Inc. spins out of Seattle Children’s Hospital, hitting the ground running with its lead CAR-T drug program already in the clinic for #DIPG and exclusive license to novel CAR T-cell technology developed at Seattle Children’s for #CNStumors. #CARTcells #BrainChildTargetsCNSCancer https://lnkd.in/ee4Seuwf
-